International Journal of Contemporary Research In Multidisciplinary

Research Article

Enlightening the Concept of Gouty Arthritis W.S.R. To *Paithika Vatashonita*: A Contemporary and Ayurvedic Review

Dr. Akhil Sharma [1*], Prof. Remani KK [2]

[1] Ph.D. Scholar, Department of Kayachikitsa, The Glocal University, Saharanpur, Uttar Pradesh, India

[2] Professor Emeritus, Research, Department of Kayachikitsa, The Glocal University, Saharanpur, Uttar Pradesh, India

Corresponding Author: * Dr. Akhil Sharma

DOI: https://doi.org/10.5281/zenodo.22112139

Abstract

Background: Acute Gouty Arthritis is a metabolic inflammatory arthropathy driven by hyperuricemia and monosodium urate (MSU) crystal deposition, causing severe joint pain, swelling, and redness. Linked to dietary imbalance, obesity, and metabolic disorders, its presentation closely resembles Paithika Vatarakta in Ayurveda, involving Pitta, Vata, and Rakta.

Aim: To correlate the pathophysiology, diagnosis, and management of Acute Gouty Arthritis with Paithika Vatashonita.

Methods: We reviewed classical texts like the Brihat Trayi (e.g., Charaka Samhita Ch. 29) and Laghu Trayi (e.g., Madhava Nidana Ch. 23) alongside modern medical history from Hippocrates to Garrod [16]. Recent clinical trials (2015–2025) on treatments like Kokilaksha Ghanavati and Guduchi Kashaya were analysed for their effects on swelling, pain, and uric acid. We compared modern crystal-induced pathology with the Ayurvedic concept of Avarana, where polluted Rakta blocks Vata to cause joint inflammation.

Results: Modern science identifies MSU crystal deposition and IL-1β-mediated inflammation, whereas Ayurveda describes Paithika Vatashonita through vitiated Rakta and aggravated Vata-Pitta, producing Daha (burning), Shotha (swelling), and Vedana (pain). Concepts like Ama and Vata-Rakta Sammurchana align seamlessly with the modern inflammatory-metabolic framework.

Conclusion: Shared etiological factors, pathogenesis, and clinical features confirm a strong conceptual correlation between Acute Gouty Arthritis and Paithika Vatarakta, offering a robust Ayurvedic framework for understanding and managing acute gout flares.

Manuscript Information

- **ISSN No:** 2583-7397
- **Received:** 12-07-2026
- **Accepted:** 20-08-2026
- **Published:** 26-08-2026
- **IJCRM:**5(4); 2026: 926-932

- **Plagiarism Checked:** Yes
- **Peer Review Process:** Yes

How to Cite this Article

Sharma A, Remani K K. Enlightening the Concept of Gouty Arthritis W.S.R. To Paithika Vatashonita: A Contemporary and Ayurvedic Review. Int J Contemp Res Multidiscip. 2026;5(4):926-932.

Access this Article Online

www.multiarticlesjournal.com

KEYWORDS: Acute Gouty Arthritis, Hyperuricemia, Paithika Vatarakta, Vatarakta, Rakta Dushti, Ayurveda

1. INTRODUCTION

Acute Gouty Arthritis is a common and increasingly important inflammatory metabolic arthropathy characterized by sudden-onset severe joint pain accompanied by swelling, redness, warmth, tenderness and restriction of movement. It represents the acute inflammatory manifestation of hyperuricemia and deposition of monosodium urate (MSU) crystals. The disease affects approximately 1–4% of the adult population globally, with its prevalence varying according to age, sex, metabolic status and lifestyle factors [1, 2]. The growing prevalence of obesity, metabolic syndrome, hypertension, chronic kidney disease, dietary imbalance, alcohol consumption and sedentary lifestyle has contributed significantly to its increasing clinical burden [1, 3].

Acute attacks commonly involve the first metatarsophalangeal joint, although the ankle, knee, wrist, elbow and other peripheral joints may also be affected [4]. Hyperuricemia facilitates the deposition of MSU crystals within joints and periarticular tissues. These crystals activate the innate immune response, particularly the NLRP3 inflammasome, leading to the release of interleukin-1β, recruitment of neutrophils and acute synovial inflammation [6, 7]. This inflammatory cascade produces the characteristic manifestations of severe pain, swelling, erythema, local warmth and tenderness.

Management is primarily directed towards rapid control of inflammation and pain during acute attacks, followed by prevention of recurrent episodes and long-term control of hyperuricemia [8]. NSAIDs, colchicine and corticosteroids are commonly used during acute attacks, whereas urate-lowering drugs such as allopurinol and febuxostat are employed for long-term management [8, 9, 14]. However, adverse effects, contraindications, drug interactions and associated comorbidities may limit the use of these therapies in certain individuals [15].

Acute Gouty Arthritis does not have a direct one-to-one disease entity; however, its clinical presentation shows considerable similarity with Paithika Vatarakta. Paithika Vatarakta is characterized by the pathological involvement of aggravated Vata Dosha, vitiated Rakta Dhatu and predominance of Pitta Dosha. Classical Nidana includes excessive intake of Lavana, Amla, Katu, Kshara, Snigdha and Ushna substances, alcohol consumption, Viruddhahara, Adhyashana, Ajirnashana, Divaswapna, Ratri Jagarana and lack of physical activity [10–12]. Several of these factors show conceptual similarity with contemporary risk factors associated with Acute Gouty Arthritis, particularly dietary indiscretion, alcohol consumption and sedentary lifestyle.

The Samprapti of Paithika Vatarakta involves vitiation of Rakta Dhatu and aggravation of Vata Dosha, with vitiated Rakta producing Margavarana of Vata. This results in further aggravation of Vata and additional vitiation of Rakta, culminating in Vata-Rakta Sammurchana and localization of the pathological process in the joints [10, 13]. With predominance of Pitta Dosha, characteristic manifestations such as Daha, Raga, Ushnata, Shotha, Vedana and Sparshasahatva occur [10]. These correspond to burning sensation, redness, warmth, swelling, pain and tenderness respectively, and show considerable clinical similarity with the cardinal features of Acute Gouty Arthritis.

Although Acute Gouty Arthritis and Paithika Vatashonita demonstrate substantial similarities in their clinical presentation, the correlation cannot be considered an absolute one-to-one equivalence. The modern understanding of Acute Gouty Arthritis is based on hyperuricemia, MSU crystal deposition and crystal-induced inflammatory pathways [6], whereas Ayurveda explains Paithika Vatashonita through the pathological interaction of Vata, Pitta and Rakta, including Margavarana and Vata-Rakta Sammurchana [10].

Therefore, there is a need for a systematic conceptual comparison of the two conditions. Reviewing the descriptions available in the Brihat Trayi, Laghu Trayi, other relevant Ayurvedic literature, contemporary medical literature and recent clinical developments can help identify similarities as well as differences in Nidana, Samprapti, clinical manifestations, diagnosis and management. Such a comparative approach may provide a clearer Ayurvedic framework for understanding the acute inflammatory and metabolic presentation of gout while recognizing the distinct conceptual foundations of both systems.

2. AIM AND OBJECTIVES

Aim:

To correlate the pathophysiology, diagnosis and management of Acute Gouty Arthritis with Paithika Vatashonita.

Objectives:

1. To explore and review the concept of Paithika Vatashonita in the classical Ayurvedic texts.
2. To correlate the contemporary pathogenesis of Acute Gouty Arthritis with the Ayurvedic Samprapti of Paithika Vatashonita.
3. To review the contemporary management protocols for Acute Gouty Arthritis.

3. LITERATURE REVIEW

Acute Gouty Arthritis

Gouty arthritis is a chronic metabolic and inflammatory disorder defined by hyperuricemia and the deposition of monosodium urate (MSU) crystals in joints, periarticular tissues, cartilage and other connective tissues [3]. It arises from disturbances in purine metabolism that lead to elevated serum uric acid levels, resulting in recurrent episodes of acute arthritis, potential tophi formation, and joint damage [3, 4].

Causative Factors (Etiology)

Gout is a multifactorial disorder driven by a combination of genetic, environmental, and host factors [4].

- **Gender and Age:** It is significantly more prevalent in men than women [2]. Premenopausal women are protected by the uricosuric effects of estrogen, but risk increases post-menopause as serum uric acid concentrations rise [1].
- **Dietary and Lifestyle Factors:** Excessive consumption of alcohol (especially beer), purine-rich foods (such as red meat, organ meats, and seafood), and fructose-rich beverages are well-established triggers [3]. Obesity,

emotional stress, recurrent dehydration, and prolonged fasting also contribute significantly.

- **Medications:** Drug-induced gout can be precipitated by medications that reduce renal urate excretion, including low-dose aspirin, thiazide and loop diuretics, cyclosporine, and certain chemotherapeutic agents [5].
- **Associated Medical Conditions:** Conditions like chronic kidney disease, hypertension, metabolic syndrome, and diabetes mellitus frequently predispose individuals to hyperuricemia [4]. Disorders with high cellular turnover (e.g., psoriasis, leukemia) also cause secondary gout through excessive uric acid production.
- **Genetic Factors:** Genetic variations regulating uric acid metabolism, particularly those affecting renal urate transporters like URAT1, GLUT9, ABCG2, and enzymatic genes like XDH and PRPS1, heavily influence susceptibility [3, 4].

Pathophysiology of Acute Gouty Arthritis

The core biochemical requirement for gout is hyperuricemia, typically defined as a serum uric acid concentration exceeding 6.8-7.0 mg/dL [5].

- **Mechanism of Accumulation:** This saturation threshold is surpassed either due to impaired renal uric acid excretion (seen in about 63% of patients) or metabolic overproduction of uric acid (seen in about 10% of patients) [3].
- **The Inflammatory Cascade:** When serum urate surpasses solubility limits, MSU crystals precipitate and deposit within the synovial fluid and periarticular tissues. Resident macrophages phagocytose these crystals, activating the NLRP3 inflammasome [6]. This triggers the release of pro-inflammatory cytokines, specifically interleukin-1β (IL-1β), which initiates massive neutrophil recruitment [7].
- **Clinical Result:** This intense, rapid inflammatory response produces the classic signs of an acute gout flare: sudden and severe joint pain, swelling, erythema, warmth, and marked tenderness [7].

Flow chart: Pathogenesis of Acute Gouty Arthritis

Purine metabolism abnormality
↓
Increased uric acid production / decreased renal excretion
↓
Hyperuricemia
↓
MSU crystal formation and deposition
↓
Activation of innate immune response
↓
NLRP3 inflammasome activation
↓
IL-1β release
↓
Neutrophil recruitment
↓
Acute synovial inflammation
↓
Pain + redness + swelling + warmth + tenderness
↓
Acute Gouty Arthritis

Clinical Features of Acute Gouty Arthritis

The principal clinical manifestations of Acute Gouty Arthritis include: Sudden severe joint pain, Joint swelling, Redness or erythema, Local warmth, Marked tenderness, and Restricted joint movement [5].

Diagnosis

- **Laboratory Diagnosis:** The gold standard for confirming gout is the identification of MSU crystals in the synovial fluid using compensated polarized light microscopy [5]. The crystals appear as needle-shaped structures exhibiting strong negative birefringence. Assessment of 24-hour urinary uric acid can also help classify if a patient is an overproducer or an under-excreter.
- **Radiological Diagnosis:** While early conventional radiography may only reveal soft tissue swelling, chronic cases show characteristic juxta-articular erosions with overhanging margins (referred to as "punched-out" lesions) [8]. Ultrasonography is highly valuable for detecting early crystal deposition, characteristically showing the "double contour sign" on the cartilage surface [8].

Management of Gouty Arthritis

- **Acute Management:** The primary goal is the rapid suppression of inflammation [9]. NSAIDs (e.g., indomethacin, naproxen) are the first-line pharmacological treatment. Colchicine is highly effective if administered within the first 12-24 hours of an attack [14]. Glucocorticoids are used for patients who cannot tolerate NSAIDs or colchicine, and biologic agents targeting IL-1β (like anakinra) are reserved for refractory cases [8].
- **Urate-Lowering Therapy (ULT):** Long-term management requires maintaining serum urate levels below 6 mg/dL, or below 5 mg/dL for patients with severe/tophaceous gout [8]. Allopurinol (a xanthine oxidase inhibitor) is the standard first-line agent, with febuxostat serving as an alternative [15]. Uricosuric agents (like probenecid) are used for underexcreters, and Pegloticase is indicated for severe refractory cases [8, 9].
- **Prophylaxis and Prevention:** Because initiating ULT can paradoxically trigger acute flares, patients are prescribed low-dose colchicine or NSAIDs as prophylaxis during the first 3-6 months of ULT therapy [14, 15]. Long-term prevention hinges on lifestyle modifications, including weight reduction, strict limitation of alcohol and purine-rich foods, and hydration [15].

4. AYURVEDIC VIEW

NIRUKTI

The term Vatarakta is derived from the combined pathological involvement of Vata Dosha and Rakta Dhatu. Chakrapani

explains the condition as: "Vatashonitaabhyam janito vyadhihi Vataraktam." Thus, the disorder arising from the pathological interaction of Vata and Rakta is termed Vatarakta or Vatashonita [10].

DEFINITION OF VATARAKTA

The classical description states: "Vayuh vivriddho vriddhena raktena avaritha pathi krtsnam samdushayet raktham tajneyam Vatashonitam." [10, 13]. The description indicates that aggravated Vata Dosha, when obstructed in its normal pathway by vitiated Rakta Dhatu, further contributes to the pathological alteration of Rakta. This pathological interaction is described as Vatashonita, commonly referred to as Vatarakta. In the present conceptual review, the Pitta-predominant manifestation of this pathological process is considered in relation to Paithika Vatarakta and the acute inflammatory presentation of Acute Gouty Arthritis.

NIDANA OF PAITHIKA VATARAKTA

According to Ayurvedic descriptions, *Paithika Vatarakta* develops due to factors capable of aggravating *Vata*, vitiating *Rakta* and promoting *Pitta* predominance. The important *Nidana* include [10–12]:

- Excessive consumption of Lavana, Amla, Katu and Kshara Ahara
- Excessive intake of Snigdha and Ushna dietary substances
- Consumption of Masha, Kulattha, Mulaka and Nishpava
- Excessive intake of Madya
- Viruddhahara, Adhyashana, Ajirnashana
- Divaswapna, Ratri Jagarana
- Lack of physical activity and Excessive sexual activity
- Psychological factors such as *Krodha* and *Shoka*

These factors demonstrate conceptual overlap with several contemporary risk factors associated with Acute Gouty Arthritis, particularly dietary excess, alcohol consumption, obesity-associated lifestyle patterns and physical inactivity. However, the Ayurvedic *Nidana* and modern risk factors should be regarded as parallel concepts rather than direct equivalents [10–12].

SAMPRAPTI OF PAITHIKA VATARAKTA

The pathogenesis of Paithika Vatarakta begins with exposure to causative factors leading to Rakta Dushti and Vata Prakopa. Dietary factors such as excessive intake of Ushna, Amla, Lavana, Katu and Vidahi substances contribute to Rakta Dushti, while irregular dietary practices, excessive exertion and other Vata-provoking factors contribute to Vata Prakopa [10].

The vitiated Rakta produces Margavarana of Vata, obstructing its normal movement. As a consequence, Vata becomes further aggravated and contributes to additional vitiation of Rakta. This reciprocal pathological interaction results in Vata-Rakta Sammurchana. The vitiated Dosha-Dushya subsequently localize in the joints and produce the clinical manifestations of *Vatarakta* [10, 13]. When *Pitta* predominates, features characteristic of Paithika Vatarakta become prominent [10].

Flow chart of Vatarakta Samprapti:

Nidana Sevana
↓
Rakta Dushti + Vata Prakopa
↓
Dushta Rakta
↓
Margavarana of Vata
↓
Vata Prakopa
↓
Further vitiation of Rakta
↓
Vata-Rakta Paraspara Dushti
↓
Dosha-Dushya Sammurchana
↓
Localization in Sandhi
↓
Vatarakta

SAMPRAPTI GHATAKA OF VATARAKTA

Samprapti Ghataka	Description
Dosha	Vata predominant Tridoshaja
Dushya	In Uttana Vatarakta: Twak, Rasa, Rakta, Mamsa; in Gambhira Vatarakta: Meda, Asthi, Majja
Upadhatu	Sira, Snayu, Kandara, Twak
Mala	Sweda
Agni	Jatharagni and Dhatvagni Dushti
Srotodushti	Sanga and Atipravritti
Srotas	Rasavaha, Raktavaha, Mamsavaha, Medovaha, Asthivaha and Majjavaha
Adhisthana	Twak, Mamsa and Sandhi
Rogamarga	Madhyama

CLINICAL FEATURES OF PAITHIKA VATARAKTA

- **Purvarupa:** The classical Purvarupa (prodromal symptoms) of Vatarakta present as a complex combination of systemic and localized features, including Atisveda, Asveda, Karshnya, and Sparshabhava [10]. As the pathology initiates, individuals may also experience Shaithilya, Alasya, Sadana, and Pidakodgama.
- This early phase is further characterized by sensory alterations and physical discomforts such as Nistoda, Sphurana, Bheda, Gaurava, Supti, Kandu, Ruka, and Daha. Additionally,

structural and localized prodromal signs manifest throughout the body via Vaivarnya, Mandalotpatti, Stambha, Spandana, Daurbalya, Angsada, and Shopha [10].

- **Rupa:** The clinical manifestations described in Paithika Vatarakta include: Daha (burning sensation), Vedana (pain), Raga (redness), Ushnata (local heat or warmth), Shotha (swelling), Sparshasahatva (tenderness or intolerance to touch), Paka (inflammatory changes), Trishna (thirst), Sweda (sweating), Bhrama (giddiness), Murchha (fainting), and Sammoha (altered awareness) [10]. Among these manifestations Daha, Raga, Ushnata, Shotha, Vedana and Sparshasahatva are particularly relevant to the correlation with Acute Gouty Arthritis [10].

UPADRAVAS

As Vatashonita progresses, it produces severe localized and systemic Upadravas (complications) [10]. Localized joint issues include Sandhi vikriti (deformity), Stabdhata (stiffness), Shula (pain), Shopha (swelling), Paka (suppuration), Sankocha (contractures), Pangu (lameness), and Mamsa Kotha (tissue necrosis). Systemically, prolonged Rakta dushti triggers Jvara (fever), Aruchi (anorexia), Aswapna (insomnia), and Daurbalya (weakness). In advanced stages, this escalates into Bhrama (giddiness), Murccha (fainting), Moha (delusion), respiratory issues (Swasa/Kasa), Visarpa (cellulitis), Marmagraha (affliction of vital parts), and profound Mamsa/Prana Kshaya (depletion of tissue and vitality) [10].

Role of Ama and Mandagni in Vatashonita

In Vatashonita, dietary errors such as Ajeernasana (eating during indigestion), Vishamashana (irregular eating), and improper Panchakarma procedures severely weaken the digestive fire (Agnimandya), leading to the production of Ama (undigested toxins) [10, 12]. This accumulated Ama causes Srotorodha (channel obstruction), which disrupts the natural equilibrium and movement of the Doshas. The obstruction heavily aggravates Vata by blocking its pathways and simultaneously vitiates Pitta, which subsequently contaminates the Rakta Dhatu (blood). Ultimately, this Ama-driven metabolic imbalance creates the exact pathological environment required for the mutual pathogenic interaction of obstructed Vata and impure Rakta, culminating in the clinical manifestation of Vatarakta [10].

Correlation of Acute Gouty Arthritis with Paithika Vatarakta

Acute Gouty Arthritis is an acute inflammatory joint disorder characterized by sudden severe pain, swelling, redness, local warmth, tenderness and restriction of joint movement [5]. Its clinical presentation demonstrates considerable similarity with Paithika Vatarakta, particularly when Pitta and Rakta are predominantly involved along with Vata. In Acute Gouty Arthritis, deposition of monosodium urate (MSU) crystals within the joint initiates an intense inflammatory response, producing pain, swelling, erythema, warmth and tenderness [6, 7]. These manifestations can be conceptually correlated with Vata-associated Vedana and Pitta-Rakta manifestations such as Raga, Daha, Shotha and Ushnata described in Paithika Vatarakta [10].

Ayurveda describes Vatarakta as a pathological condition arising from the interaction of aggravated Vata Dosha and vitiated Rakta Dhatu. The vitiated Rakta obstructs the normal movement of Vata, resulting in Margavarana, further aggravation of Vata and subsequent Vata-Rakta Sammurchana [10]. When Pitta predominates in this pathological process, features such as Daha, Raga, Ushnata, Shotha, Vedana and Sparshasahatva become prominent. The similarity of these manifestations with Acute Gouty Arthritis provides a basis for considering Paithika Vatarakta as a clinically relevant Ayurvedic framework for understanding the acute inflammatory phenotype of gout [16].

Acute Gouty Arthritis	Paithika Vatarakta
Severe acute joint pain	Vedana
Burning sensation	Daha
Redness/erythema	Raga
Local warmth	Ushnata
Joint swelling	Shotha
Tenderness	Sparshasahatva
Restricted joint movement	Impaired Sandhi Cheshta
Acute inflammatory presentation	Pitta Pradhanyata

Ayurvedic Management of Paithika Vatarakta

The management of Paithika Vatarakta is directed towards correction of the underlying Dosha-Dushya imbalance, reduction of Pitta and Rakta Dushti, regulation of Vata and prevention of recurrence [10].

- **Shodhana:** Virechana, Ghrita and Ksheera Panam and Basti (Ksheera Basti).
- Raktamokshana with Jaloka
- **Shamana (External Therapies):** Seka, Nirvapana
- **Shamana (Internal Therapies):** In Paittika Vatarakta, Ghrita or Ksheera processed with Vari (Shatavari), Tikta (Katuka), Patola, Triphala and Amrita (Guduchi) should be consumed. Alternatively, ghee or milk processed with drugs possessing predominantly Madhura and Tikta Rasa may be administered.
- Kokilaksha Kashayam, Kaishore Guggulu, Amrita Guggulu, Pinda Tailam, Sarivadi Tailam, Madhuyastyadi Tailam, Shatavari Tailam, Mahapinda Tailam, Shatavari Ghritam, Guduchi Ghritam, Amritadi Ghritam, Mahatiktam Ghritam, Mahaguduchi Ghritam, Amritadi Kwath, Patoladi Kwath, Guluchyadi Kwath etc. [10-12].

PATHYA AND APATHYA

Category	Modern Concept (Gouty Arthritis)	*Ayurvedic* Concept *(Vatarakta)*
Apathya (Unwholesome Foods)	Alcohol (especially beer); Red meat, organ meat, and seafood (purine-rich foods); Fructose-rich beverages and sugar-sweetened drinks [3].	Fermented/sour drinks like Madira, Sura, Asava, Kanji, Dadhi, and Takra; Marshy, aquatic, or dry meats (Anupa, Ambuja, Shushka mamsa); Heavy (Guru), salty (Lavana), sour (Amla), and pungent (Katu) foods, including Masha and Kulattha [10].
Apathya (Unwholesome Lifestyle)	Obesity and sedentary lifestyle; Emotional stress; Prolonged fasting and recurrent dehydration [3, 4].	Stholya (obesity) and Achakramana shilta (sedentary lifestyle); Krodha (anger) and Shoka (grief); Divaswapna (day sleep), Ratri Jagarana (night waking), and Langhana (excessive fasting) [10, 11].
Pathya (Wholesome Foods)	Low-fat dairy products; Balanced diets restricted in purines [15].	Milk (Godugdha, Ajadugdha) and fresh ghee (Naveen ghrita); Old barley (Puranyava), wheat (Godhuma), and Shashtika rice; Vegetables like Shatavari, Bathua, Patola, and pulses like Mudga (green gram) [10, 12].
Pathya (Wholesome Lifestyle)	Weight reduction and maintenance of adequate hydration [15].	Hydration through light, liquid-based diets like Yusha (medicated soups) [10].

5. DISCUSSION

The clinical manifestations of Paithika Vatarakta demonstrate substantial similarity with those observed during Acute Gouty Arthritis. In particular, Daha, Raga, Ushnata, Shotha, Vedana and Sparshasahatva correspond closely with burning sensation, redness, local warmth, swelling, severe pain and tenderness observed during an acute gouty attack [10, 16]. This clinical overlap provides an important basis for considering Paithika Vatarakta as a relevant Ayurvedic framework for understanding the acute inflammatory phenotype of gout.

A second area of similarity is the role of dietary and lifestyle factors. Classical Nidana such as inappropriate dietary intake, Madya Sevana, Adhyashana, Ajirnashana, Divaswapna and physical inactivity show conceptual parallels with several contemporary risk factors associated with Acute Gouty Arthritis [3, 10]. However, these similarities should not be interpreted as evidence that individual Ayurvedic Nidana are direct equivalents of specific biochemical risk factors.

The Ayurvedic concept of Margavarana, in which vitiated Rakta obstructs the normal movement of Vata, provides a theoretical explanation for the pathological interaction between Vata and Rakta [10]. In Acute Gouty Arthritis, MSU crystal deposition initiates an innate immune response involving NLRP3 inflammasome activation and inflammatory mediator release [6]. Although both descriptions explain an inflammatory process localized to the joint, Margavarana should not be equated directly with MSU crystal deposition or NLRP3 activation. Rather, the two represent different explanatory frameworks for understanding the disease.

The predominance of Pitta in Paithika Vatarakta is particularly relevant to Acute Gouty Arthritis because of the marked inflammatory manifestations observed during the acute phase. Similarly, the progressive joint manifestations described in advanced Vatarakta may be considered clinically comparable to the functional impairment and structural complications associated with recurrent or chronic gout [16]. Nevertheless, the proposed relationship remains a conceptual correlation and requires validation through clinical and translational research.

Viewing this condition through the Ayurvedic framework offers distinct clinical advantages. The predominance of Pitta in Paithika Vatarakta is highly relevant to the marked inflammation observed during the acute phase, allowing for personalized, targeted treatments that focus on cooling and blood-purification rather than just pain suppression [10]. Furthermore, Ayurveda goes beyond symptom management by addressing the root metabolic errors through detailed dietary modifications and detoxification. This proactive lifestyle approach is highly advantageous for preventing the progressive joint manifestations and structural complications seen in advanced Vatarakta and recurrent chronic gout [12, 15].

Ultimately, these similarities highlight the immense potential for an integrative medical approach. Clinicians can combine the rapid diagnostic accuracy and fast-acting pain relief of modern medicine with Ayurvedic strategies designed for long-term metabolic correction and structural joint preservation. By treating the acute flare with targeted interventions and the chronic metabolic state with Ayurvedic principles, patients receive comprehensive, whole-body care [16]. Nevertheless, while the clinical overlap is clear, aligning concepts like Margavarana directly with biochemical immune activation remains a conceptual correlation that requires further validation through clinical and translational research.

6. CONCLUSION

The clinical presentation of Acute Gouty Arthritis demonstrates considerable similarity with the Pitta-Rakta-predominant manifestations of Paithika Vatarakta. The correspondence of Daha, Raga, Ushnata, Shotha, Vedana and Sparshasahatva with burning sensation, redness, warmth, swelling, pain and tenderness provides a significant clinical basis for this correlation [10, 16]. Similarities are also observed in several dietary and lifestyle-related etiological factors.

From the Ayurvedic perspective, the interaction of Vata, Rakta and Pitta, together with the concepts of Margavarana and Vata-Rakta Sammurchana, provides a distinctive framework for understanding the disease [10]. However, Paithika Vatarakta should not be regarded as an exact biomedical equivalent of Acute Gouty Arthritis. The correlation is more appropriately understood as a clinical and conceptual relationship between two different systems of disease interpretation [16]. Further clinical, pharmacological and translational research is required to validate this correlation and determine its relevance for evidence-based Ayurvedic management of Acute Gouty Arthritis.

REFERENCES

1. Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-662.
2. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(2):155-175.
3. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039-2052.
4. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-1855.
5. Neogi T. Clinical practice: gout. N Engl J Med. 2011;364(5):443-452.
6. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241.
7. So, A, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639-647.
8. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760.
9. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.
10. Agnivesha. Charaka Samhita. Revised by Charaka and Dridhabala. Edited by Acharya JT. Varanasi: Chaukhambha Orientalia; 2023. Chikitsa Sthana, Chapter 29, Vatarakta Chikitsa.
11. Sushruta. Sushruta Samhita. Edited by Ambikadatta Shastri. Varanasi: Chaukhambha Sanskrit Sansthan; 2023.
12. Vagbhata. Ashtanga Hridaya. Edited by Harishastri Paradakara. Varanasi: Chaukhambha Surbharati Prakashan; 2022.
13. Madhavakara. Madhava Nidana. Edited by Yadunandana Upadhyaya. Varanasi: Chaukhambha Prakashan; 2019. Chapter 23, Vatarakta Nidana.
14. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare. Arthritis Rheum. 2010;62(4):1060-1068.
15. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-1446.
16. Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective—a review. J Adv Res. 2017;8(5):495-511.

About the Corresponding Author

Dr. Akhil Sharma is a Ph.D. Scholar in the Department of Kayachikitsa at The Glocal University, Saharanpur, Uttar Pradesh, India. His academic interests include Ayurvedic medicine, Kayachikitsa, clinical research, traditional therapeutic approaches, and integrative healthcare. He is actively engaged in scholarly research and academic activities related to Ayurveda and contemporary healthcare practices.